Search
Search Results
-
Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma
Immunosuppression is a hallmark of pancreatic ductal adenocarcinoma (PDAC), contributing to early metastasis and poor patient survival. Compared...
-
PCDH1, a poor prognostic biomarker and potential target for pancreatic adenocarcinoma metastatic therapy
BackgroundPancreatic adenocarcinoma (PAAD) is an aggressive solid tumour characterised by few early symptoms, high mortality, and lack of effective...
-
Clinical and biological markers predictive of treatment response associated with metastatic pancreatic adenocarcinoma
BackgroundChemotherapy for metastatic pancreatic adenocarcinoma (PDAC) offers limited benefits, but survival outcomes vary. Reliable predictive...
-
A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line therapy in metastatic pancreatic adenocarcinoma
BackgroundThere are no standard third-line treatment options for metastatic pancreatic ductal adenocarcinoma (mPDAC). Trametinib in combination with...
-
Treatment outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma: a real world study
BackgroundA majority of patients undergoing curative intent surgery for pancreatic ductal adenocarcinoma (PDAC) will unfortunately develop recurrent...
-
Panoramic tumor microenvironment in pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is notorious for its resistance to various treatment modalities. The genetic heterogeneity of PDAC, coupled...
-
Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer
Metastasis occurs frequently after resection of pancreatic cancer (PaC). In this study, we hypothesized that multi-parametric analysis of...
-
Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma
BackgroundSystemic inflammatory scores may aid prognostication and patient selection for trials. We compared five scores in advanced pancreatic...
-
High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospective study
AimsWe previously showed that the nab-paclitaxel plus S-1 (NPS) regimen had promising effects against metastatic pancreatic ducal adenocarcinoma...
-
A Phase 2 study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer
BackgroundNivolumab with modified FOLFIRINOX (mFOLFIRINOX) may have additive antitumour effects while minimising chemotherapy cytotoxicity. We...
-
Crosstalk Between Peripheral Innervation and Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive lethal malignancy, characterized by late diagnosis, aggressive growth, and therapy...
-
Survival outcome of different treatment sequences in patients with locally advanced and metastatic pancreatic cancer
BackgroundDespite some therapeutic advances, improvement in survival rates of unresectable and/or metastatic pancreatic ductal adenocarcinoma (PDAC)...
-
Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe
BackgroundReal-world data on treatment patterns/outcomes for metastatic pancreatic cancer (mPAC) are limited. This study aims to assess real-world...
-
Deciphering fatty acid biosynthesis-driven molecular subtypes in pancreatic ductal adenocarcinoma with prognostic insights
PurposePancreatic ductal adenocarcinoma (PDAC) poses a significant challenge due to its high heterogeneity and aggressiveness. Recognizing the...
-
Comparative immune profiling of pancreatic ductal adenocarcinoma progression among South African patients
BackgroundPancreatic Ductal Adenocarcinoma (PDAC) is an aggressive cancer characterized by an immunosuppressive microenvironment. Patients from...
-
Features of metabolism associated molecular patterns in pancreatic ductal adenocarcinoma
Exploring pancreatic ductal adenocarcinoma (PDAC) metabolic landscape would contribute to further understand PDAC from the metabolic perspective and...
-
Early outcomes of MR-guided SBRT for patients with recurrent pancreatic adenocarcinoma
BackgroundLocal treatment options for locally recurrent pancreatic adenocarcinoma (LR-PAC) are limited, with median survival time (MST) of...
-
High pyroptosis activity in pancreatic adenocarcinoma: poor prognosis and oxaliplatin resistance
BackgroundPyroptosis, as a type of inflammatory programmed cell death, has been studied in inflammatory diseases and numerous cancers but its role in...
-
Acid sphingomyelinase expression is associated with survival in resectable pancreatic ductal adenocarcinoma
AbstractPancreatic adenocarcinoma (PDAC) is one of the most common cancers worldwide. Unfortunately, the prognosis of PDAC is rather poor, and for...
-
Pancreatic cancer epigenetics: adaptive metabolism reprograms starving primary tumors for widespread metastatic outgrowth
Pancreatic cancer is a paradigm for adaptation to extreme stress. That is because genetic drivers are selected during tissue injury with epigenetic...
